Barr expecting
This article was originally published in The Tan Sheet
Executive Summary
CEO Bruce Downey believes Barr has "met the standard the FDA laid out for us in the letter denying our [Plan B switch] application a few months ago," the exec said Feb. 2, explaining the firm's expectation of receiving an "approvable letter" from the agency. "We followed the recommendation, we followed the pathway that was sort of suggested in that letter, I think we have done it...professionally, done it appropriately and we have met all reasonable objections." FDA failed to act on the application by the PDUFA deadline of Jan. 21 (1"The Tan Sheet" Jan. 24, 2005, p. 6)...
You may also be interested in...
No Plan B Switch Parade As User Fee Deadline Comes And Goes
FDA will deliver a decision in the "near future" on whether the Plan B emergency contraceptive pill is "approvable" for over-the-counter use in women age 16 and up, according to manufacturer Barr Labs
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.